



Biocon opens COVID-19 vaccination centre at Syngene campus in Bengaluru

13 April 2021 | News

The Biocon Group is the 1st Corporate entity to kickstart this vaccination centre in Bengaluru

The Biocon Group of Companies has inaugurated a Vaccination Centre at the Bengaluru campus of Syngene International Limited as part of the nationwide drive for mass vaccination of individuals above 45 years of age to protect them against COVID-19.

The group has started vaccinating all eligible employees in keeping with its commitment to ensure the health and safety of its workforce. As a responsible corporate citizen, it will also work closely and in partnership with the Government of Karnataka to create awareness and offer this service to all people who are eligible in the Electronic City area of Bengaluru.

The Biocon Group is the 1st Corporate entity to kickstart this vaccination centre in Bengaluru.

Kiran Mazumdar Shaw, Executive Chairperson, Biocon, said, "We feel proud and privileged that the Government of Karnataka has given us the first permission as a corporate to initiate vaccination drive for our employees. We will be working closely and in partnership with the government to roll out this vaccination drive, create awareness and offer this service to all people who are eligible in the Electronic City area of Bengaluru, apart from our own employees."

Dr Mahesh Bhalgat, Chief Operating Officer, Syngene International Limited, said, "The Biocon Group is committed to ensuring the safety and wellbeing of its workforce. Since July 2020, we are proactively testing our employees to identify infection cases and immediately quarantine them and provide necessary medical support. We are now happy to provide free vaccination for our employees and their family. This is an extension of our commitment to safeguarding our employees' health as well as a reflection of our commitment to support the government's efforts to combat and contain the pandemic."

As a part of its commitment to address the novel coronavirus pandemic in India, the Biocon Group is also offering a comprehensive portfolio of products for treating mild to severely ill COVID-19 patients. They have introduced ARAFLU® (Favipiravir) in addition to Cytosorb® and ALZUMAB-L™, and Syngene is manufacturing Remdesivir under a voluntary

licensing agreement with Gilead.